Economic evaluation of artesunate and three quinine regimens in the treatment of severe malaria in children at the Ebolowa Regional Hospital-Cameroon: a cost analysis

Table 5 Summary of total cost in USD by cost headings according to treatment alternatives

Cost headings	ARTES (n = 30)		QLD (n = 28)			QNLD3 (n = 30)			QNLD2 (n = 30)
Cost headings	Cost per group	Cost per patient	Cost per group	Cost per patient	p value	Cost per group	Cost per patient	p value	Cost per group	Cost per patient	p value
Anti-malaria drugs	231.57	7.72	67.68	2.42	<0.001	73.32	2.44	<0.001	78.96	2.63	<0.001
Nursing care materials	103.47	3.50	97.37	3.477	0.49	104.86	3.50	0.44	102.71	3.42	0.61
Adjuvant care materials	619.24	20.64	560.56	20.02	0.48	566.95	18.90	0.57	498.61	16.62	0.99
Laboratory Investigations	635.25	21.17	620.74	22.16	0.58	798.87	26.63	0.17	726.85	24.23	0.53
Admission	147.50	4.92	170	6.07	0.03	192.5	6.42	0.005	167.5	5.58	0.02
Professional fees	217.05	7.24	230.77	8.24	0.33	255.18	8.51	0.25	232.51	7.75	0.57
Total and mean cost per treatment alternative (95% CI)	1954.08	65.14 (57.68–72.60)	1747.12	62.40 (52.67–72.13)	0.21	1991.68	66.40 (57.03–75.77)	0.67	1807.14	60.23 (51.55–68.91)	0.24

ISSN: 1475-2875